China SXT Pharmaceuticals raises $10M in discounted share sale
What's the deal? China SXT Pharmaceuticals, a traditional Chinese medicine maker listed on Nasdaq, has raised roughly $10 million through a registered direct offering of 66,666,666 Class A ordinary shares priced at $0.15 each. Univest SecuritiesDealroom has a profile for this one. Try Dealroom → served as sole placement agent.
Why now? The offering runs under a shelf registration statement on Form F-3 that took effect on December 1, 2025. The deal, which includes an option for pre-funded warrants in place of shares, is set to close on or about January 12, 2026, subject to customary conditions.
What's the endgame? The company has framed the raise as a step to strengthen its financial position.
What could go wrong? Issuing a large volume of new shares risks diluting existing holders. The $0.15 price sits below typical market levels, a discount that could point to weak investor confidence.
The signal: Small-cap issuers turning to discounted direct offerings underscores how tight capital access has become for Nasdaq-listed firms outside the spotlight — trading dilution for cash on hand.
Read more: AInvest
